 | This articlerelies excessively onreferences toprimary sources. Please improve this article by addingsecondary or tertiary sources. Find sources: "Trubion" – news ·newspapers ·books ·scholar ·JSTOR(May 2009) (Learn how and when to remove this message) |
 | |
| Company type | Public company |
|---|---|
| Nasdaq: TRBN | |
| Industry | Biopharmaceutical |
| Founded | 1999 |
| Fate | acquired byEmergent BioSolutions (2010) |
| Headquarters | Seattle, WA |
| Products | Protein-based therapeutics |
| Website | www.trubion.com |
Trubion was a publicly heldbiopharmaceutical company that was focused on creating a pipeline of protein-based therapeutic product candidates to treatautoimmune andinflammatory diseases andcancer. Trubion was acquired byEmergent BioSolutions on October 28, 2010.[1] Trubion was established in 1999 in theState of Washington as an early stage development company, and was later reincorporated in October 2002 in theState of Delaware.
In December 2005, Trubion entered into a collaborative agreement withWyeth[2] for the development and worldwide commercialization ofCD20-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion's contract with Wyeth extended through December 22, 2009.
| Name | Platform | Indication | Status | Collaboration | Research |
|---|---|---|---|---|---|
| TRU-015 | SMIP | Rheumatoid arthritis | Phase 2b | Wyeth | Phase 2b initiation[3] EULAR data[4] |
| SBI-087 | SMIP | Rheumatoid arthritis | Phase 1 | Wyeth | Recent data[4] |
| SBI-087 | SMIP | Systemic lupus erythematosus | Phase 1 | Wyeth | |
| TRU-016 | SMIP | Chronic lymphocytic leukemia | Phase 1/2 | Trubion Proprietary Technology | ASCO 2008 Poster Presentation[5] |
| TRU-016 | SMIP | Non-Hodgkin lymphoma | Pre-clinical | Trubion Proprietary Technology | |
| TRU-016 | SMIP | Autoimmune disease and inflammation | Pre-clinical | Trubion Proprietary Technology |
Trubion's product development efforts were focused on three technology pillars: SMIP protein therapeutics, SCORPION protein therapeutics, and TRU-ADhanCe potency enhancing technology for immunopharmaceuticals.
SMIP, orsmall modular immunopharmaceutical, therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion worked on SMIP drug candidates that targeted validated antigens with the same specificity and predictable biological activity asmAbs.
SCORPION protein therapeutics are also single chain polypeptides composed of functional domains from naturally occurring proteins. The difference between SMIP and SCORPION technologies is that SCORPION compounds are multi-specific therapeutics that are capable of targeting two or more antigens simultaneously.
TRU-ADhanCe potency enhancing technology was designed to enhance the potency of existing therapies that work through Fc-directed or antibody-directed cellular cytotoxicity, orADCC. TRU-ADhanCe technology could be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longerin vivo half lives.
{{cite web}}: CS1 maint: archived copy as title (link)